TG Therapeutics
TGTX
63.34
-1.54
-2.37%
TG Therapeutics
US · TGTX
#1638 by market cap
Listed 1970
63.34
-1.54
-2.37%
Periodic snapshot; not a real-time feed.
· 2026-11-20 20:02
✦ Quant Ownership Signal how this is computed
Accumulating
- The number of reporting institutions increased by 17 in the most recent period (2026/Q3).
- Total institutional ownership rose 4.6 percentage points.
Ownership vs. money flow
AlignedInstitutions added shares last reporting period, and the stock has seen net inflows in main-fund flow over the last 20 trading sessions - the two line up.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Institutional ownership
- Held by institutions
- 88.72% +4.59pp
- Institutions
- 521 +17
- As of
- 2026/Q3 vs. prior period
Holder types
Mutual Fund63.19%
Hedge Fund14.80%
Public Company6.14%
Individual/Insider4.68%
Private Company1.73%
Government Pension Fund1.66%
Insurance Company0.93%
Family Office/Trust0.22%
Other6.62%
Top holders as of 2026-09-30
BlackRock
16.16% · 22.63M sh
State Street Global Advisors
5.98% · 8.49M sh
Vanguard Portfolio Management, LLC
5.62% · 7.88M sh
Vanguard Capital Management, LLC
4.47% · 6.26M sh
Michael Weiss
3.50% · 4.90M sh
Opus Point Partners
3.48% · 4.87M sh
Geode Capital Management, LLC
2.64% · 3.70M sh
D. E. Shaw & Co., L.P.
2.43% · 3.40M sh
Soleus Capital Management, L.P.
2.09% · 2.93M sh
T. Rowe Price Group, Inc.
1.98% · 2.77M sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
47 filings tracked · 21 buys · 26 sells
| Name | Role | Stake |
|---|---|---|
| Michael Weiss | Chairperson & CEO | 3.50% |
| Sean Power | CFO, Corporate Secretary & Treasurer | 0.49% |
| Kenneth Hoberman | Independent Director | 0.20% |
| Yann Echelard | Independent Director | 0.16% |
| Daniel Hume | Independent Director | 0.14% |
| Laurence Charney | Lead Independent Director | 0.12% |
| Sagar Lonial | Independent Director | 0.07% |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-09-09 | Laurence Charney | Lead Independent Director | Open Market Disposition | -5,000 | $54.96 |
| 2026-08-06 | Laurence Charney | Lead Independent Director | Other Disposition | -6,050 | -- |
| 2026-06-10 | Laurence Charney | Lead Independent Director | Other Derivative Acquisition | +8,325 | -- |
| 2026-06-10 | Kenneth Hoberman | Independent Director | Other Derivative Acquisition | +8,325 | -- |
| 2026-06-10 | Yann Echelard | Independent Director | Other Derivative Acquisition | +8,325 | -- |
| 2026-06-10 | Sagar Lonial | Independent Director | Other Derivative Acquisition | +8,325 | -- |
| 2026-06-10 | Daniel Hume | Independent Director | Other Derivative Acquisition | +8,325 | -- |
| 2026-01-28 | Laurence Charney | Lead Independent Director | Other Disposition | -43,197 | -- |
| 2026-01-07 | Michael Weiss | Chairperson & CEO | Other Acquisition | +622,000 | -- |
| 2026-01-07 | Sean Power | CFO, Corporate Secretary & Treasurer | Other Acquisition | +90,000 | -- |
| 2025-11-23 | Yann Echelard | Independent Director | Open Market Disposition | -5,000 | $32.57 |
| 2025-11-04 | Michael Weiss | Chairperson & CEO | Other Disposition | -4,668,843 | -- |
| 2025-09-10 | Sagar Lonial | Independent Director | Open Market Disposition | -20,852 | $32.24 |
| 2025-06-12 | Yann Echelard | Independent Director | Open Market Disposition | -10,000 | $36.94 |
| 2025-06-11 | Laurence Charney | Lead Independent Director | Other Acquisition | +21,408 | -- |
| 2025-06-11 | Kenneth Hoberman | Independent Director | Other Acquisition | +14,718 | -- |
| 2025-06-11 | Yann Echelard | Independent Director | Other Acquisition | +14,718 | -- |
| 2025-06-11 | Sagar Lonial | Independent Director | Other Acquisition | +14,718 | -- |
| 2025-06-11 | Daniel Hume | Independent Director | Other Acquisition | +14,718 | -- |
| 2025-03-16 | Daniel Hume | Independent Director | Other Disposition | -62,459 | -- |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-11-20 20:02:20 · For reference only, not investment advice and not tailored to your situation.
TG Therapeutics discussion 0 comments